F9 and hemophilia B: Factor IX and etanercept proteins are currently used to treat hemophilia B and rheumatoid arthritis, respectively, and both of these biologics are being assessed as AAV transgenes in clinical trials (Evans et al., 2008; Nathwani et al., 2014).